Semaglutide Market Hits Speed Bump with ₹100 Crore Excess Stock
The rapid expansion of India’s obesity therapy market has encountered a significant setback as sluggish sales lead to an inventory glut. After an explosive start driven by generic entries, the semaglutide segment is now struggling with a massive buildup of unsold stock across the trade channel.
The Inventory Glut: A ₹100 Crore Overhang
The much-hyped semaglutide therapy market is facing an early crisis as stockists and wholesalers grapple with excess inventory. Industry estimates suggest that the value of unsold stock currently sitting in the trade channel is approximately ₹100 crore.
According to Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), the market is seeing an inventory overhang where distributors are holding 50–60 days of stock. This is significantly higher than the industry standard of 30–45 days. As a result, channel partners have hit the pause button on fresh procurement from pharmaceutical manufacturers, waiting for existing stocks to liquidate before placing new orders.
From Hyper-Growth to Sluggish Momentum
The current slowdown follows a period of unprecedented volatility. In April, the ₹2,000-crore obesity therapy market experienced a massive surge, with value growth jumping 50% month-on-month and volumes increasing by 88%. This explosion was largely triggered by the patent expiry of semaglutide on March 20, which allowed major players like Sun Pharma, Dr. Reddy's, and Torrent to flood the market with cheaper generic versions.
However, the momentum lost steam in May. Data from market research firm Pharmarack indicates that month-on-month value growth plummeted to just 6%, while unit growth slowed to 12%. This sudden deceleration has left manufacturers and distributors caught off guard by the rapid shift in demand.
Regulatory Shifts and Competitive Landscape
Industry experts suggest that the moderation in sales might not be purely a matter of supply and demand but could be linked to tightening regulatory oversight. Government advisories and prescribing restrictions introduced in April stipulate that GLP-1 therapies must only be prescribed by qualified specialists. These guidelines are expected to influence prescribing patterns and potentially temper the "off-label" use often associated with weight loss.
Despite the semaglutide slowdown, the broader GLP-1 receptor agonist market shows resilience through other products. Mounjaro (tirzepatide), marketed by Eli Lilly, remains the dominant force in the pharma market. In May, Mounjaro saw its sales rise by 12% to reach ₹136 crore, proving that the appetite for advanced obesity and diabetes management remains high even as specific generic segments stabilize.
Key Takeaways
- Inventory Crisis: The trade channel is currently burdened with nearly ₹100 crore worth of excess semaglutide stock, with wholesalers holding up to 60 days of inventory.
- Growth Deceleration: After an 88% volume surge in April following patent expiry, May saw a sharp decline in momentum, with value growth slowing to just 6%.
- Regulatory Impact: New government guidelines requiring specialist prescriptions for GLP-1 therapies are believed to be a contributing factor to the recent cooling of demand.